ATE223712T1 - Pharmazeutische zusammensetzung von l-dopa ethyl ester - Google Patents

Pharmazeutische zusammensetzung von l-dopa ethyl ester

Info

Publication number
ATE223712T1
ATE223712T1 AT96923037T AT96923037T ATE223712T1 AT E223712 T1 ATE223712 T1 AT E223712T1 AT 96923037 T AT96923037 T AT 96923037T AT 96923037 T AT96923037 T AT 96923037T AT E223712 T1 ATE223712 T1 AT E223712T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
ethyl ester
dopa ethyl
dopa
carrier
Prior art date
Application number
AT96923037T
Other languages
English (en)
Inventor
Sasson Cohen
Yoram Sela
Ruth Levy
Nava Shterman
Eldad Melamed
Daphne Atlas
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE223712T1 publication Critical patent/ATE223712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96923037T 1995-07-21 1996-07-18 Pharmazeutische zusammensetzung von l-dopa ethyl ester ATE223712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US136895P 1995-07-21 1995-07-21
PCT/IL1996/000058 WO1997003662A1 (en) 1995-07-21 1996-07-18 Pharmaceutical composition of l-dopa ethyl ester

Publications (1)

Publication Number Publication Date
ATE223712T1 true ATE223712T1 (de) 2002-09-15

Family

ID=21695690

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923037T ATE223712T1 (de) 1995-07-21 1996-07-18 Pharmazeutische zusammensetzung von l-dopa ethyl ester

Country Status (12)

Country Link
US (1) US5840756A (de)
EP (1) EP0840603B1 (de)
JP (1) JPH11509547A (de)
AT (1) ATE223712T1 (de)
AU (1) AU6368596A (de)
CA (1) CA2227208A1 (de)
DE (1) DE69623634T2 (de)
DK (1) DK0840603T3 (de)
ES (1) ES2184881T3 (de)
IL (1) IL123010A (de)
PT (1) PT840603E (de)
WO (1) WO1997003662A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376545B1 (en) * 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
GB0114198D0 (en) * 2001-06-11 2001-08-01 Syngenta Ltd Herbicidal composition
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
CA2553156A1 (en) * 2003-10-20 2005-05-12 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
RU2440100C2 (ru) * 2005-03-28 2012-01-20 Орексо Аб Новые фармацевтические композиции, полезные в лечении болезни паркинсона
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20070178149A1 (en) * 2005-11-07 2007-08-02 Moshe Flashner-Barak Levodopa compositions
ES2391575T3 (es) 2005-12-05 2012-11-27 Xenoport, Inc. Mesilato de profármaco de Levodopa, sus composiciones y sus usos
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
JP2012505885A (ja) * 2008-10-20 2012-03-08 ゼノポート，インコーポレーテッド レボドパエステルプロドラッグを合成する方法
AU2010315892B2 (en) 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP3054929B1 (de) 2013-10-07 2020-08-05 Impax Laboratories, LLC Mukoadhäsive levodopa-formulierungen mit gesteuerter freisetzung und/oder levodopa-ester und verwendungen davon
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
DK0840603T3 (da) 2003-01-20
PT840603E (pt) 2003-01-31
EP0840603B1 (de) 2002-09-11
WO1997003662A1 (en) 1997-02-06
DE69623634D1 (de) 2002-10-17
DE69623634T2 (de) 2003-05-22
CA2227208A1 (en) 1997-02-06
EP0840603A1 (de) 1998-05-13
IL123010A0 (en) 1998-08-16
AU6368596A (en) 1997-02-18
JPH11509547A (ja) 1999-08-24
US5840756A (en) 1998-11-24
IL123010A (en) 2003-11-23
ES2184881T3 (es) 2003-04-16

Similar Documents

Publication Publication Date Title
ATE223712T1 (de) Pharmazeutische zusammensetzung von l-dopa ethyl ester
RS49633B (sr) Farmaceutske formulacije koje sadrže vorikonazol
RU94028653A (ru) Фармацевтический препарат
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
ID23806A (id) Komposisi-komposisi farmasi untuk pemberian oral yang terdiri dari bahan aktif dan siklodekstrin
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
DE69637964D1 (de) Derivaten von Nodulisporen Säure
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
SE9602442D0 (sv) Administration of pharmaceuticals
DK0460062T3 (da) Huperzin A-analoger
ID22763A (id) Komposisi penstabil tibolon
NO980296L (no) Forbedrede terapeutiske midler
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
NO982229D0 (no) Svovelholdige di-tert-butylfenol-forbindelser anvendbare som antiinflammatoriske midler
SE9504662D0 (sv) New compounds
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
MA26447A1 (fr) Analogues peptidiques de la lh-rh, leurs utilisations et compositions pharmaceutiques en contenant
BR9813102A (pt) Derivados de ácido metilenobisfosfÈnico novos
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
FR2732604B1 (fr) Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
TR200100887T2 (tr) LH-RH analoglarının ağız yoluyla verilmesi için alfa-siklodekstrin esaslı farmasötik terkipler
DE69820301D1 (de) Neue krystalline polymorphe form von 1-methyl-5-p-toluoylpyrrol-2-acetamidoessigsäure guaiacyl ester (med 15)
SE9504594D0 (sv) The use of an ester inositoltrisåhosphate for the preparing of medicaments

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0840603

Country of ref document: EP

REN Ceased due to non-payment of the annual fee